Hearse D J
The Rayne Institute, St Thomas' Hospital, London, UK.
Mol Cell Biochem. 1998 Sep;186(1-2):177-84.
The objectives of this article are to: (i) discuss the origins and the nature of ischemic injury, (ii) identify factors influencing the evolution of injury, (iii) consider various cellular targets for ischemic injury, (iv) assess the overall importance of 'reperfusion injury', (v) discuss conceptual approaches to cardioprotection and (vi) to identify new ideas and approaches in the realm of myocardial protection. In the human heart, myocardial ischemia may take many forms, it may exist for periods as short as a few seconds or minutes, it may last for hours or it may persist for years. In terms of discussing interventions to combat myocardial ischemia, this article will focus on: (i) regional ischemia as occurs during evolving myocardial infarction and (ii) whole heart or global ischemia as occurs during cardiac surgery and transplantation.
(i)讨论缺血性损伤的起源和本质,(ii)确定影响损伤演变的因素,(iii)考虑缺血性损伤的各种细胞靶点,(iv)评估“再灌注损伤”的总体重要性,(v)讨论心脏保护的概念方法,以及(vi)确定心肌保护领域的新思想和方法。在人类心脏中,心肌缺血可能有多种形式,可能持续短短几秒或几分钟,可能持续数小时,也可能持续数年。在讨论对抗心肌缺血的干预措施方面,本文将重点关注:(i)进展性心肌梗死期间发生的局部缺血,以及(ii)心脏手术和移植期间发生的全心或整体缺血。